Filtered By:
Drug: Beta-Blockers
Countries: South Korea Health
This page shows you your search results in order of date.
Order by Relevance | Date
Total 28 results found since Jan 2013.
Treatment delay and outcomes of ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention during the COVID-19 era in South Korea
CONCLUSION: Reperfusion after STEMI treatment during the COVID-19 period was delayed; therefore, efforts should be made to improve on reperfusion.PMID:35811367 | PMC:PMC9271717 | DOI:10.3904/kjim.2022.077
Source: The Korean Journal of Internal Medicine - July 11, 2022 Category: Internal Medicine Authors: Seok Oh Myung Ho Jeong Kyung Hoon Cho Min Chul Kim Doo Sun Sim Young Joon Hong Ju Han Kim Youngkeun Ahn Source Type: research
Incidence and Mortality Associated with Cardiovascular Medication among Hypertensive COVID-19 Patients in South Korea
CONCLUSION: In South Korea, beta-blockers exhibited potential benefits in lowering the incidence of COVID-19 among hypertensive patients. Furthermore, CCBs may lower the hospital mortality rate among hypertensive COVID-19 patients. These findings were also applied to the general adult population, regardless of hypertension.PMID:34164954 | DOI:10.3349/ymj.2021.62.7.577
Source: Yonsei Medical Journal - June 24, 2021 Category: Universities & Medical Training Authors: Tak Kyu Oh Hyoung Won Cho Jung Won Suh In Ae Song Source Type: research
